ClinicalTrials.gg
Active, not recruitingNCT06168461Updated Oct 28, 2026

Daily Aspirin Treatment After Preeclampsia

An Early Phase 1 interventional study of Aspirin and Placebo in Preeclampsia, sponsored by Anna Stanhewicz, PhD. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science

How we know

Updated Oct 28, 2026Now Active, not recruitingStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.

Planned enrollment
47th of 52
40 · median 235
Started
2023
with 6 others
Phase 1
4 of 52
2 open now
Primary completion
2026-06
later than 4 of 21 live
Registered
37th of 52
by date
Lead sponsor
1 of 52
Anna Stanhewicz, PhD

Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 47th largest by planned enrollment, is one of 7 that started in 2023, is one of 4 in phase 1, reaches primary completion later than 4 of the 21 other live ones, and was the 37th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing aspirin in Pre-Eclampsia, or all of them as a file.
02

Study summary

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

03

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • preeclampsia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • had preeclampsia in the past 5 years,
  • 18 years or older

Exclusion criteria

Exclusion criteria:

  • current daily aspirin use,
  • skin diseases,
  • current tobacco or nicotine use (including vaping),
  • diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced \< 60 mL/min/1.73m2,
  • statin or other cholesterol-lowering medication,
  • current antihypertensive medication,
  • history of hypertension prior to pregnancy,
  • history of gestational diabetes,
  • currently pregnancy,
  • \<18.5 kg/m2,
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergies to study drugs,
  • bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    placebo pill taken once daily at bedtime for 12 weeks

    Drug: Placebo

  • Experimental
    aspirin

    162mg aspirin taken once daily at bedtime for 12 weeks

    Drug: Aspirin

Interventions

  • 162mg aspirin capsule

  • DrugPlacebo

    placebo capsule

06

What researchers measure

Primary outcomes

  1. magnitude of microvascular endothelial function

    skin blood flow response to acetylcholine delivered via intradermal microdialysis

    Time frame: baseline, 12 weeks

  2. magnitude of brachial artery endothelial function

    brachial artery flow mediated dilation

    Time frame: baseline, 12 weeks

  3. magnitude of microvascular endothelin-1 mediated constriction

    skin blood flow response to endothelin-1 delivered via intradermal microdialysis

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. magnitude of microvascular nitric oxide-dependent dilation

    skin blood flow response to acetylcholine + L-NAME delivered via intradermal microdialysis

    Time frame: baseline, 12 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2026, 31 months.

Of 20 phase 1 interventional studies under Pre-Eclampsia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 31 months is above that.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Feb 2027, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Dec 13, 2023
StartActual
Nov 1, 2023
Primary completionActual
Jun 30, 2026
CompletionEst.
Feb 2027was Jun 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 28, 2026
Study completion
Jun 2026→Feb 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Active, not recruiting
    Study completion Jun 2026→Feb 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06168461
Lead sponsor
Anna Stanhewicz, PhD
Responsible party
Anna Stanhewicz, PhD (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Dec 13, 2023
Start date
Nov 1, 2023
Primary completion
Jun 30, 2026
Completion
Feb 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion